Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Paul R Buckley, Julie Chan, Cynthia Bishop, Timothy Woo, Katrina Todd, Elizabeth Phillips, Alessia Bottos, Christopher R. Bolen, Verena Passerini, Oliver Weigert, Piers E.M. Patten

Blood (2024) 144 (Supplement 1): 4382.

https://doi.org/10.1182/blood-2024-209877

Published: 2024

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Marina Bacac, Johannes Sam, Won Seog Kim, Gareth P. Gregory, Matthew Ku, Sylvia Herter, Christian Klein, Pablo Umana, Stephen Simko, Victor Orellana-Noia, Linda Lundberg, Alessia Bottos

Blood (2024) 144 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2024-200753

Published: 2024

Journal Articles

Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy

Cristina Zucchinetti, Chiara Signori, Martina di Trani, Maria Cristina Pirosa, Alessio Bruscaggin, Koorosh Korfi, Alessia Bottos, Eleonora Calabretta, Francesco Corrado, Davide Rossi, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 4356.

https://doi.org/10.1182/blood-2024-207596

Published: 2024

Journal Articles

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Matthew Matasar, Toby A. Eyre, Eva Gine, Audrey Filézac De L'Étang, Ben Byrne, Linda Lundberg, Alejandra Padovani, Christophe Boetsch, Alessia Bottos, Naseer Qayum

Blood (2023) 142 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2023-173946

Published: 2023

Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel

Blood (2023) 142 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2023-181723

Published: 2023

Journal Articles

Imaging Mass Cytometry Reveals a Highly Heterogenous Cell Makeup of the Follicular Lymphoma Tumour Microenvironment

Paul Buckley, Julie Chan, Laura Jouvin, Cynthia Bishop, Timothy Woo, Katrina Todd, Elizabeth Phillips, Alessia Bottos, Piers EM Patten

Blood (2023) 142 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2023-182037

Published: 2023

Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2023-174213

Published: 2023

Journal Articles

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Sina Nassiri, Stephan Schmeing, Gabrielle Leclercq, Sylvia Herter, Llucia Alberti Servera, Tamara Hüsser, Emilio Yángüez, Diana Dunshee, Koorosh Korfi, Pablo Umana, Ann-Marie E. Bröske, Alessia Bottos, Marina Bacac

Blood (2023) 142 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2023-179776

Published: 2023

Journal Articles

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Mark Bishton, Corinna Woestmann, Franck Morschhauser, Toby A. Eyre, Maria Shin, Aaron Schroeder, Anton Belousov, Haocheng Li, Andrea Knapp, Michael C. Wei, Enkhtsetseg Purev, Alessia Bottos

Blood (2022) 140 (Supplement 1): 3555–3556.

https://doi.org/10.1182/blood-2022-157256

Published: 2022

Journal Articles

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Verena Passerini, Vindi Jurinovic, Christopher R Bolen, Andrea Knapp, Alessia Bottos, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Andrew Davies, Robert Marcus, Michael von Bergwelt, Tina Nielsen, Martin H. Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert

Blood (2021) 138 (Supplement 1): 39.

https://doi.org/10.1182/blood-2021-147751

Published: 2021

Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti

Blood (2021) 138 (Supplement 1): 525.

https://doi.org/10.1182/blood-2021-148359

Published: 2021

Journal Articles

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

Skander Jemaa, Samuel Tracy, Alessia Bottos, Alex de Crespigny, Thomas Bengtsson, Tina G Nielsen, Joseph N Paulson

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134780

Published: 2020

NARROW

Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Imaging Mass Cytometry Reveals a Highly Heterogenous Cell Makeup of the Follicular Lymphoma Tumour Microenvironment

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only